Physician profile
Jonathan Alexander
NPI 1710921754
$12,250.29
in general payments reported to CMS, 2019-2025
10 companies · $15.75 in 2025
The $15.75 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $6,343 · 2021: $5,140 · 2022: $15.63 · 2023: $364 · 2024: $34.91 · 2025: $15.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $414.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,841.66 | 2020-2021 | |
| Lilly USA, LLC | $5,373.13 | 2020-2021 | |
| Pfizer INC. | $226.33 | 2019-2021 | |
| Astellas Pharma US INC | $216.17 | 2019-2023 | Lexiscan |
| E.R. Squibb & Sons, L.L.C. | $193.06 | 2021-2023 | Camzyos, Eliquis |
| Abbott Laboratories | $187.57 | 2019-2023 | Cardiomems |
| Novartis Pharmaceuticals Corporation | $90.51 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $80.94 | 2019-2021 | |
| Amarin Pharma, INC. | $22.46 | 2019-2020 | |
| Novo Nordisk INC | $18.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.